人福医药：熊去氧胆酸胶囊获得药品注册证书

Core Viewpoint - Yichang Renfu, a subsidiary of Renfu Pharmaceutical (600079), has received the drug registration certificate for Ursodeoxycholic Acid Capsules from the National Medical Products Administration, indicating a significant regulatory approval for the company [1]. Group 1: Product Approval - The approved indications for Ursodeoxycholic Acid Capsules include: (1) cholesterol gallstones that are X-ray penetrable and with normal gallbladder contraction function; (2) cholestatic liver diseases such as primary biliary cirrhosis; (3) bile reflux gastritis [1].